Cardiac Papillary Fibroelastoma: Source of Cerebral Embolism Treated With Intravenous Thrombolysis

Matijević, Vesna; Poljaković, Zdravka; Ilić, Ivana; Čikeš, Ivo; Habek, Mario

doi:10.1016/j.jstrokecerebrovasdis.2010.02.013

Cited by 9 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…411 At least 2 case reports have described treatment with intravenous alteplase without hemorrhagic complication. 412,413 Intracardiac Mass: Recommendations 1. For patients with major acute ischemic stroke likely to produce severe disability and cardiac myxoma, treatment with intravenous alteplase may be reasonable (Class IIb; Level of Evidence C).…”

Section: Intracardiac Massmentioning

confidence: 99%

Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke

Demaerschalk¹,

Kleindorfer²,

Adeoye³

et al. 2016

Stroke

585

237

View full text Add to dashboard Cite

Purpose-To critically review and evaluate the science behind individual eligibility criteria (indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant tissue-type plasminogen activator (alteplase) treatment in acute ischemic stroke. This will allow us to better inform stroke providers of quantitative and qualitative risks associated with alteplase administration under selected commonly and uncommonly encountered clinical circumstances and to identify future research priorities concerning these eligibility criteria, which could potentially expand the safe and judicious use of alteplase and improve outcomes after stroke. Methods-Writing group members were nominated by the committee chair on the basis of their previous work in relevant topic areas and were approved by the American Heart Association Stroke Council's Scientific Statement Oversight Committee and the American Heart Association's Manuscript Oversight Committee. The writers used systematic literature reviews, references to published clinical and epidemiology studies, morbidity and mortality reports, clinical and public health guidelines, authoritative statements, personal files, and expert opinion to summarize existing evidence and to indicate gaps in current knowledge and, when appropriate, formulated recommendations using standard American Heart Association criteria. All members of the writing group had the opportunity to comment on and approved the final version of this document. The document underwent extensive American Heart Association internal peer review, Stroke The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on September 24, 2015, and the American Heart Association Executive Committee on October 5, 2015. A copy of the document is available at http://my.americanheart.org/statements by selecting either the "By Topic" link or the "By Publication Date" link. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@ wolterskluwer.com.The online-only Data Supplement, which contains literature search strategies and Figures A, B, and C, is available with this article at http://circ. ahajournals.org/lookup/suppl/doi:10.1161/STR.0000000000000086/-/DC1.The American Heart Association requests that this document be cited as follows: Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy EI, Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE; on behalf of the American Heart Association Stroke Council and Council on Epidemiology and Prevention. Scientific rational...

show abstract

Section: Intracardiac Massmentioning

confidence: 99%

Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke

Demaerschalk¹,

Kleindorfer²,

Adeoye³

et al. 2016

Stroke

585

237

View full text Add to dashboard Cite

show abstract

“…To date, there have been several case reports, which showed patients with and without good outcome after treatment . The case of patient with cardiac papillary fibroelastoma was also published, but without long‐term history . Material from the tumour or thrombus attached to it could cause cerebrovascular embolism, which may explain the clinical improvement in some patients .…”

Section: Discussionmentioning

confidence: 99%

Safety of intravenous thrombolysis for acute ischaemic stroke including concomitant neoplastic disease sufferers - experience from Poland

et al. 2015

View full text Add to dashboard Cite

show abstract

“…PFEs are typically asymptomatic, although they remain a possible source of cerebral emboli, either from the tumor itself or from fibrin thrombi attached to its surface (5,6). In this case, r-TPA therapy achieved partial recanalization of the basilar artery; therefore, the mechanical clot disruption that followed was necessary to achieve additional thrombolytic effects.…”

Section: Discussionmentioning

confidence: 97%

An Infrequent Type of Stroke with an Unusual Cause and Successful Therapy: Basilar Artery Occlusion Caused by a Cardiac Papillary Fibroelastoma Recanalized 12 Hours after Onset

et al. 2013

Self Cite

View full text Add to dashboard Cite

We herein report the case of a 32-year-old woman with sudden onset ataxia, limb dysmetria and somnolence. Emergency radiological findings showed bilateral cerebellar and thalamic infarctions as a result of a basilar artery occlusion. The patient was treated with intra-arterial (IA) and mechanical thrombolysis 12 hours after symptom onset and showed an excellent recovery. A diagnostic workup revealed a tumor mass on the mitral valve that was surgically removed, while a histological analysis confirmed a diagnosis of cardiac papillary fibroelastoma.

show abstract

Cardiac Papillary Fibroelastoma: Source of Cerebral Embolism Treated With Intravenous Thrombolysis

Cited by 9 publications

References 7 publications

Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke

Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke

Safety of intravenous thrombolysis for acute ischaemic stroke including concomitant neoplastic disease sufferers - experience from Poland

An Infrequent Type of Stroke with an Unusual Cause and Successful Therapy: Basilar Artery Occlusion Caused by a Cardiac Papillary Fibroelastoma Recanalized 12 Hours after Onset

Contact Info

Product

Resources

About